


**Product Name** : Elacridar  
**Cat. No.** : PC-45887  
**CAS No.** : 143664-11-3  
**Molecular Formula** : C<sub>34</sub>H<sub>33</sub>N<sub>3</sub>O<sub>5</sub>  
**Molecular Weight** : 563.6429  
**Target** : P-glycoprotein (P-gp)  
**Solubility** : 10 mM in DMSO



## Biological Activity

Elacridar (GF120918, GW-0918) is a potent inhibitor of multidrug resistance (MDR, P-gp) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC<sub>50</sub> of 0.02 μM. Elacridar (GF120918, GW-0918) effectively competes with [3H]azidopine for binding P-glycoprotein. Elacridar (GF120918, GW-0918) restores sensitivity of the tumor to a single dose of doxorubicin in mice; orally bioavailable.

## References

Hyafil F, et al. *Cancer Res.* 1993 Oct 1;53(19):4595-602.  
den Ouden D, et al. *Leukemia.* 1996 Dec;10(12):1930-6.  
Witherspoon SM, et al. *Clin Cancer Res.* 1996 Jan;2(1):7-12.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com